10-K: Cardinal Health Reports Strong FY26 Growth

Cardinal Health, Inc. announced a 14% revenue increase to $254.2 billion and a 30% rise in non-GAAP operating earnings to $3.6 billion for fiscal year 2026.

Summary

• Cardinal Health reported a 14% increase in revenue for fiscal year 2026, reaching $254.2 billion, driven primarily by branded and specialty pharmaceutical sales.
• Non-GAAP operating earnings saw a significant 30% increase to $3.6 billion, attributed to growth in the Pharma segment and acquisitions.
• GAAP operating earnings grew 15% to $2.6 billion, supported by the Pharma segment and GMPD segment performance, but was impacted by a $184 million goodwill impairment charge.
• The company completed the acquisition of Solaris Health for approximately $1.9 billion, expanding its presence in the urology MSO market.
• Cash and equivalents increased to $4.9 billion, with operating activities providing $5.2 billion in net cash.
• The company returned $1.4 billion to shareholders through share repurchases and paid $2.04 per share in dividends.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth and increased operating earnings, despite some specific charges and impairments.

Positives

• Revenue increased by 14% to $254.2 billion in fiscal year 2026.
• Non-GAAP operating earnings increased by 30% to $3.6 billion.
• GAAP operating earnings increased by 15% to $2.6 billion.
• The Pharma segment saw a 15% revenue increase and a 23% profit increase.
• The GMPD segment profit increased by 91%.
• The company successfully acquired Solaris Health, strengthening its MSO platform.
• Cash and equivalents increased to $4.9 billion.
• Shareholder returns through buybacks and dividends were substantial.

Negatives

• A $184 million pre-tax goodwill impairment charge was recognized for the Navista & ION reporting unit.
• Interest expense increased by 62% to $348 million due to additional debt financing for acquisitions.
• The company recognized a $122 million pre-tax impairment charge related to its equity interest in Outcomes.
• Tariff impacts continue to present challenges, although mitigation efforts are in place.

Risks

• Regulatory and licensing requirements are rigorous and non-compliance could adversely affect operations.
• Cybersecurity threats pose a risk, with potential for material impact on business operations and data.
• Concentration of sales and credit with significant customers, like CVS Health, presents a risk.
• Acquisition integration and management carry risks, including potential diversion of management attention and unforeseen liabilities.
• Changes in U.S. healthcare policy and reimbursement levels could negatively impact the business.
• Reliance on suppliers and potential supply chain disruptions due to geopolitical events or other factors.
• Potential for further goodwill or long-lived asset impairment charges.
• Ongoing opioid litigation and settlement obligations continue to pose financial and operational risks.

Future Outlook

The company expects capital expenditures in fiscal 2027 to be approximately $700 million, primarily for manufacturing and distribution infrastructure and technology investments. Future dividend payments are at the discretion of the Board of Directors.

Management Comments

• The performance of The Specialty Alliance positively impacted the year-over-year comparison of Pharma segment profit during fiscal 2026, primarily due to the impact of the acquisitions of GI Alliance and Solaris Health.
• Demand growth for GLP-1 medications began to moderate in fiscal year 2026 and we expect future demand growth moderation to continue; however, demand for these medications is unpredictable.
• The tariff environment remains dynamic and we do not expect to be able to establish alternative sources of supply or otherwise mitigate the potential impact of tariffs on all of the products that we source, manufacture, or distribute.

Industry Context

StockSavvy.ai notes that Cardinal Health's performance aligns with broader trends in the healthcare distribution and services sector, showing resilience and growth driven by strategic acquisitions and strong demand in its pharmaceutical segment, despite ongoing industry challenges like tariffs and regulatory scrutiny.

Legal Proceedings

• Ongoing opioid litigation and investigations, with $4.3 billion accrued as of June 30, 2026.
• Civil Investigative Demand from the Department of Justice regarding a 2022 transaction involving a group purchasing organization and a rheumatology managed services organization.
• Product liability lawsuits involving Cordis IVC filter products, with most claims settled.
• Ongoing legal proceedings with insurers related to reimbursement for defense and indemnity costs for opioid-related lawsuits.

Stakeholder Impact

• Shareholders benefit from increased revenue, earnings, and continued share repurchases and dividends.
• Customers may see benefits from MSO acquisitions and improved supply chain efficiency.
• Employees are impacted by the company's growth and strategic initiatives, with ongoing focus on talent management and compensation.
• Suppliers may experience continued demand from Cardinal Health's large-scale operations.

Next Steps

• Continue integration of recent acquisitions, including Solaris Health.
• Manage ongoing opioid litigation and settlement obligations.
• Monitor and mitigate the impact of tariffs and evolving regulatory environments.
• Execute on capital deployment strategy, including share repurchases and dividends.

Key Dates

Recommendation

While Cardinal Health demonstrated strong revenue and non-GAAP earnings growth, the significant goodwill impairment charge, increased interest expense due to acquisitions, and ongoing legal/regulatory risks warrant a cautious approach. The company is executing well on its strategy, but the integration of large acquisitions and resolution of legal matters introduce uncertainties that balance the positive financial performance.

Keywords

Cardinal Health, 10-K, Fiscal Year 2026, Financial Results, Pharmaceutical Distribution, Medical Products, Acquisitions, Healthcare Services